Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - omega-3-acid ethyl esters 90, quantity: 1000 mg - capsule, soft - excipient ingredients: purified water; gelatin; glycerol; d-alpha-tocopherol - hypertriglyceridaemia: endogenous hypertriglyceridaemia as a supplement to diet when dietary measures alone are insufficient to produce an adequate response. treatment is indicated for the following types of dyslipidaemia (fredrickson classification) only: -type iv & v as monotherapy and with close monitoring of ldl-c levels. - type iib as add-on therapy to statins, when control of triglycerides with statins has been shown to be insufficient. patients with higher baseline levels of triglycerides are more likely to exhibit a better response to omacor. omacor is not indicated in exogenous hypertriglyceridaemia (type 1 hyperchylomicronaemia). there are insufficient data to support the use in patients with secondary endogenous hypertriglyceridaemia including patients with diabetes mellitus.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

mega lifesciences sdn. bhd. - saccharomyces boulardii -

Australia - English - Department of Health (Therapeutic Goods Administration)

mannatech australia pty ltd - colecalciferol, quantity: 10.375 microgram; concentrated fish omega-3 triglycerides, quantity: 1.0443 g - capsule, soft - excipient ingredients: purified water; glycerol; gelatin; flavour; vegetable oil; dl-alpha-tocopherol; sunflower oil; mixed (low-alpha type) tocopherols concentrate; d-alpha-tocopherol - maintain/support bone health ; maintain/support heart health ; maintain/support immune system health ; maintain/support cognitive function/mental function

Australia - English - Department of Health (Therapeutic Goods Administration)

catalent australia pty ltd - concentrated fish omega-3 triglycerides,evening primrose oil,natural fish oil,potassium iodide,zinc amino acid chelate -

Australia - English - Department of Health (Therapeutic Goods Administration)

up australia pty ltd - fish oil - rich in omega-3 acids -

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - olive oil, quantity: 50 g; fish oil - rich in omega-3 acids, quantity: 30 g; medium chain triglycerides, quantity: 60 g; soya oil, quantity: 60 g - injection, intravenous infusion - excipient ingredients: glycerol; sodium oleate; dl-alpha-tocopherol; water for injections; egg lecithin; sodium hydroxide - supply of energy and essential fatty acids to patients, as part of a parenteral nutrition regimen, when oral or enteral nutrition is impossible, insufficient or contra-indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - olive oil, quantity: 50 g; fish oil - rich in omega-3 acids, quantity: 30 g; medium chain triglycerides, quantity: 60 g; soya oil, quantity: 60 g - injection, intravenous infusion - excipient ingredients: glycerol; sodium oleate; dl-alpha-tocopherol; water for injections; egg lecithin; sodium hydroxide - supply of energy and essential fatty acids to patients, as part of a parenteral nutrition regimen, when oral or enteral nutrition is impossible, insufficient or contra-indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

factors group australia pty ltd - fish oil - rich in omega-3 acids, quantity: 1 g (equivalent: eicosapentaenoic acid, qty 180 mg; equivalent: docosahexaenoic acid, qty 120 mg) - capsule, soft - excipient ingredients: gelatin; mixed (low-alpha type) tocopherols concentrate; purified water; glycerol - maintain/support joint health ; helps in the maintenance of healthy blood lipids/blood fats ; maintain/support cardiovascular system health ; maintain/support heart health ; maintain/support brain health ; maintain/support skin health

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters 900 mg - -  omega-3-acid ethyl esters is indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (≥500 mg/dl) hypertriglyceridemia (htg). -  usage considerations: patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters and should continue this diet during treatment with omega-3-acid ethyl esters. -  laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. -  limitations of use: -  the

United States - English - NLM (National Library of Medicine)

atlantic biologicals corps - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters 1 g - omega-3-acid ethyl esters capsules, usp are indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (≥500 mg/dl) hypertriglyceridemia (htg). patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, usp and should continue this diet during treatment with omega-3-acid ethyl esters capsules, usp. usage considerations: laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters capsules, usp. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consider